Skip to content
Screener

Fulgent Genetics, Inc. FLGT Therapeutic Development — Allocated Share Based Compensation Expense

Other segment segments

Laboratory Services
$7.64M-10.5%

Similar metrics at other companies

Outset Medical, Inc. logo
OMResearch And Development — Allocated Share Based Compensation Expense
$594K-20.8%
Ollie's Bargain Outlet Holdings, Inc. logo
OLLIOllies — Allocated Share Based Compensation Expense
$3.4M+7.5%
Journey Medical Corporation logo
DERMDermatological — Allocated Share Based Compensation Expense
$989K-25.2%
Genasys logo
GNSSHardware — Allocated Share Based Compensation Expense
$483K+54.3%
Genasys logo
GNSSSoftware — Allocated Share Based Compensation Expense
$68K-32.7%
Gyre Therapeutics, Inc. logo
GYREGyre — Allocated Share Based Compensation Expense
$627K-18.7%

Other financials

Income statement

See full
Revenue$71.1M-3.2%
Gross profit$21.5M-24.2%
Operating income-$34.6M-74.9%
Net income-$24.8M-115%
EPS (diluted)-$0.80-116%

Balance sheet

See full
Cash & equivalents$23.4M-65.2%
Total debt$8.2M+40.5%
Total equity$1.0B-6.9%
Total assets$1.2B-4.1%

Cash flow

See full
Operating cash flow$7.1M+260%
CapEx$5.2M+10.3%
Free cash flow$1.9M+121%

Valuation

See full
Market cap$526.64M-16.5%
Enterprise value$511.45M-6.7%
P/S1.6×-0.4×

Profitability

See full
Gross margin38.7%-0.1pp
Operating margin-33.1%+17.4pp
Net margin-23%+43.3pp
FCF margin-36.9%—

Returns & leverage

See full
Return on equity-6.8%+48.2pp
Debt / equity0×0.0×
Current ratio5.3×-1.0×

Where this comes from

Reported directly by Fulgent Genetics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AllocatedShareBasedCompensationExpense.

The source filing: Fulgent Genetics, Inc.’s 10-Q, filed May 1, 2026.

Filed
May 1, 2026, 7:08 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-199065
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Equity-based compensation
Laboratory services$7,640$8,532
Therapeutic development2,2502,018
Total$9,890$10,550

Item 1. Financial Statements.

FAQ

What is Fulgent Genetics, Inc.'s therapeutic development — allocated share based compensation expense?
Fulgent Genetics, Inc. (FLGT) reported therapeutic development — allocated share based compensation expense of $2.25M in Q1 2026.
How has Fulgent Genetics, Inc.'s therapeutic development — allocated share based compensation expense changed year-over-year?
Fulgent Genetics, Inc.'s therapeutic development — allocated share based compensation expense increased by 11.5% year-over-year, from $2.02M to $2.25M.
What does therapeutic development — allocated share based compensation expense mean?
This represents the portion of total share-based compensation expense allocated to the therapeutic development segment for employee stock-based incentives. It helps investors understand the non-cash compensation costs associated with the talent driving the segment's development efforts.

Ask your AI about Fulgent Genetics, Inc.'s therapeutic development — allocated share based compensation expense.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude